Liver transplantation for acute-on-chronic liver failure
10.3969/j.issn.1674-7445.2022.03.008
- VernacularTitle:慢加急性肝衰竭的肝移植治疗
- Author:
Qi FAN
1
;
Zhao LI
Author Information
1. Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing 100044, China
- Publication Type:Research Article
- Keywords:
Acute-on-chronic liver failure;
Liver transplantation;
Organ failure;
Model for end-stage liver disease (MELD);
Hepatitis B immunoglobulin (HBIG);
Entecavir;
Tenofovir;
Granulocyte colony-stimulating factor
- From:
Organ Transplantation
2022;13(3):333-
- CountryChina
- Language:Chinese
-
Abstract:
Acute-on-chronic liver failure (ACLF) is a specific category of liver failure, which is mainly characterized by rapid progression and multiple organ failure. At present, patients with ACLF are mainly given with systematic and comprehensive medical therapy to promote liver regeneration. However, liver transplantation is the only potentially curative treatment for patients who failed to respond to medical treatment and rapidly progress into multiple organ failure. Considering the differences of disease progression and clinical prognosis, and the shortage of donor liver in China, it is necessary to actively prevent the triggering factors of ACLF in patients with chronic liver diseases, screen out the recipients who are most likely to benefit from liver transplantation and deliver precision management during perioperative period of liver transplantation. In this article, the application of liver transplantation in ACLF was illustrated from the perspectives of accurate evaluation of ACLF, proper control of liver transplantation indications and meticulous perioperative management, aiming to optimize the therapeutic strategy of liver transplantation in patients with ACLF.
